|
 "In July, the first results could be available for the five to 12
year olds, in September for the younger children," BioNTech Chief
Executive Ugur Sahin told Spiegel. He added it takes about four to
six weeks to evaluate the data.
"If all goes well, as soon as the data is evaluated, we will be able
to submit the application for approval of the vaccine for all
children in the respective age group in different countries," he
said.
BioNTech and Pfizer asked U.S. regulators this month to approve
emergency use of their vaccine for adolescents aged 12 to 15.
Sahin was quoted by Spiegel as saying the company was "in the final
stages before submission" to European regulators for children aged
12 and older.
[to top of second column] |
 A trial published at the end of
March found the companies' COVID-19 vaccine was
safe, effective and produces robust antibody
responses in adolescents.
The Pfizer/BioNTech two-shot vaccine is already
authorized for use in those aged 16 and above.
Young people are less likely to suffer severe
cases of COVID-19 and more likely to have
asymptomatic infection, allowing them to
unwittingly transmit COVID-19 to others.
(Writing by Caroline Copley; editing by John
Stonestreet)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
